Clinical Trial

A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-16.
Trial Details
NCT Number NCT07545356
Lead Sponsor Kivu Bioscience Inc.
Conditions Solid Tumors
Enrollment 76 participants
Start Date 2026-06
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10